Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability and Gut microbIota AnalysiS of an Oral Microbiotherapy in Amyotrophic Lateral Sclerosis; an Open-label Phase 1b Pilot Trial

Trial Profile

Safety, Tolerability and Gut microbIota AnalysiS of an Oral Microbiotherapy in Amyotrophic Lateral Sclerosis; an Open-label Phase 1b Pilot Trial

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MaaT 033 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Acronyms IASO
  • Sponsors MaaT Pharma

Most Recent Events

  • 12 May 2025 According to MaaT Pharma media release, an external Scientific Advisory Committee took place at the end of March 2025 to review the full data. The Scientific Advisory Committee provided insights regarding the best population to target in a Phase 2 trial.
  • 12 May 2025 Final data readout results were presented in a MaaT Pharma media release.
  • 26 Nov 2024 According to MaaT Pharma media release, a total of 15 participants across two centers in France have been enrolled in the Phase 1 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top